CORTESI, LAURA
 Distribuzione geografica
Continente #
NA - Nord America 3.621
EU - Europa 1.277
AS - Asia 1.149
SA - Sud America 185
AF - Africa 24
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 4
Totale 6.282
Nazione #
US - Stati Uniti d'America 3.573
GB - Regno Unito 396
SG - Singapore 354
CN - Cina 316
HK - Hong Kong 175
DE - Germania 169
IT - Italia 162
BR - Brasile 148
SE - Svezia 134
VN - Vietnam 95
IE - Irlanda 77
RU - Federazione Russa 69
UA - Ucraina 59
FI - Finlandia 55
TR - Turchia 54
FR - Francia 47
ID - Indonesia 29
IN - India 28
CA - Canada 24
KR - Corea 24
BG - Bulgaria 23
AU - Australia 21
AR - Argentina 18
BE - Belgio 17
PL - Polonia 15
ZA - Sudafrica 14
MX - Messico 12
MY - Malesia 11
JP - Giappone 9
NL - Olanda 9
ES - Italia 8
AE - Emirati Arabi Uniti 7
PK - Pakistan 7
AT - Austria 6
EC - Ecuador 6
VE - Venezuela 6
BD - Bangladesh 5
PH - Filippine 5
UZ - Uzbekistan 5
GR - Grecia 4
HU - Ungheria 4
IQ - Iraq 4
IR - Iran 4
LV - Lettonia 4
MA - Marocco 4
SI - Slovenia 4
IL - Israele 3
NO - Norvegia 3
PY - Paraguay 3
TH - Thailandia 3
TW - Taiwan 3
AL - Albania 2
BZ - Belize 2
CL - Cile 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
EG - Egitto 2
GE - Georgia 2
HN - Honduras 2
LT - Lituania 2
RO - Romania 2
SA - Arabia Saudita 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CH - Svizzera 1
CO - Colombia 1
CR - Costa Rica 1
CU - Cuba 1
DK - Danimarca 1
DZ - Algeria 1
EU - Europa 1
GD - Grenada 1
GT - Guatemala 1
HR - Croazia 1
KE - Kenya 1
KZ - Kazakistan 1
LB - Libano 1
MD - Moldavia 1
MN - Mongolia 1
PA - Panama 1
PE - Perù 1
PF - Polinesia Francese 1
SD - Sudan 1
SV - El Salvador 1
TN - Tunisia 1
YE - Yemen 1
Totale 6.282
Città #
Fairfield 447
Ashburn 376
Santa Clara 277
Woodbridge 274
Southend 246
Singapore 231
Chandler 216
Seattle 199
Hong Kong 173
Houston 160
Cambridge 154
Wilmington 128
Dearborn 119
Ann Arbor 113
Jacksonville 98
Nyköping 90
Beijing 88
Dublin 76
Los Angeles 66
London 63
Hefei 58
Dallas 57
Chicago 54
New York 45
Modena 38
Izmir 35
Council Bluffs 32
San Diego 32
Munich 30
Helsinki 28
Ho Chi Minh City 28
Princeton 25
Eugene 22
Salt Lake City 22
Sofia 22
Jakarta 21
Seoul 21
Bremen 20
São Paulo 20
Shanghai 19
Moscow 16
The Dalles 16
Hanoi 15
Dong Ket 14
Lauterbourg 14
Sydney 14
Brussels 12
Buffalo 12
Fremont 12
Montreal 12
Falls Church 11
Frankfurt am Main 11
Phoenix 11
Redwood City 11
Turku 10
Warsaw 10
Haiphong 9
Guangzhou 8
Orem 8
Rome 8
Bologna 7
Columbus 7
Florence 7
Milan 7
Boardman 6
Chennai 6
Denver 6
San Giuliano Milanese 6
San Jose 6
Tokyo 6
Brooklyn 5
Elk Grove Village 5
Johannesburg 5
Kunming 5
Mexico City 5
Palermo 5
Paris 5
Rio de Janeiro 5
Tampa 5
Barcelona 4
Belo Horizonte 4
Bragança Paulista 4
Buenos Aires 4
Hounslow 4
Katowice 4
Kuala Lumpur 4
Las Vegas 4
Lübbenau 4
Modugno 4
Ottawa 4
Plainsboro 4
Portsmouth 4
Redondo Beach 4
Riga 4
Shijiazhuang 4
Waanrode 4
Ankara 3
Baltimore 3
Bronx 3
Budapest 3
Totale 4.646
Nome #
A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women 426
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 357
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 313
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat 308
Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer 305
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? 299
Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors 285
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 284
MRI in high risk women: benefits and problems 268
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 267
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes 263
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 262
MRI before initial surgery outside of clinical trials: the real world! 259
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 250
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life 250
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 248
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study 246
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 238
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 235
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 220
Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the modena familial breast and ovarian cancer center (Italy) 208
Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on italian women 201
DCE-MRI Radiomic analysis in triple negative ductal invasive breast cancer. Comparison between BRCA and not BRCA mutated patients: Preliminary results 124
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) 93
Re: Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness 85
The "popcorn" sign: the first early ultrasound sign of serous intra-parenchymal ovarian cancer in BRCA mutation carriers 39
Characterization of copy number variants in hereditary cancer patients through NGS shows a distinctive PALB2 contribution to the diagnostic yield 29
Impact of Ethnicity on Breast Cancer Outcome: A Systematic Review and Meta-Analysis of Randomized Phase III Trials of the Last Decade. 7
Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019 5
Totale 6.374
Categoria #
all - tutte 24.096
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.096


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021439 0 0 0 0 0 78 33 91 50 85 40 62
2021/2022514 26 44 70 25 20 34 18 22 52 49 98 56
2022/2023625 76 75 36 70 66 70 7 52 137 4 19 13
2023/2024380 29 23 25 24 81 25 47 54 14 7 11 40
2024/20251.137 31 8 31 56 222 161 101 81 119 39 118 170
2025/20261.212 176 66 191 220 383 176 0 0 0 0 0 0
Totale 6.374